Postibrutinib relapse outcomes for patients with marginal zone lymphoma

• Type of Material: Article
• Authors: Narenranath Epperla, Ohio State University; Qiuhong Zhao, Ohio State University; Sayan Mullick Chowdhury, Ohio State University; Lauren Shea, Washington University; Tamara K Moyo, Atrium Health; Nishitha Reddy, Vanderbilt University; Julia Sheets, University of North Carolina; David M Weiner, University of Pennsylvania; Praveen Ramakrishnan Geethakumari, University of Texas Southwestern Medical Center; Malathi Kandarpa, University of Michigan; Ximena Jordan Bruno, University of Vermont; Colin Thomas, Thomas Jefferson University; Michael C Churnetski, Emory University; Andrew Hsu, Brown University; Luke Zurbriggen, University of Wisconsin, Madison; Xiao-Wei C Tan, Cancer Institute of New Jersey; Kathryn Lindsey, Medical University of South Carolina; Joseph Maakaron, University of Minnesota, Minneapolis; Paolo F Caimi, University Hospitals Seidman Cancer Center; Pallawi Torka, Roswell Park Cancer Institute; Celeste Bello, H. Lee Moffitt Cancer Center and Research Institute; Sabarish Ayyappan, University of Iowa; Timothy S Oh, Northwestern University; Reem Karmali, Northwestern University; Seo-Hyun Kim, Rush University; Anna Kress, Yale University; Shalin Kothari, Yale University; Yazeed Sawalha, Ohio State University; Beth Christian, Ohio State University; Kevin A David, Cancer Institute of New Jersey; Irl B Greenwell, Medical University of South Carolina; Murali Janakiram, University of Minnesota, Minneapolis; Vaishalee P Kenkre, University of Wisconsin, Madison; Adam J Olszewski, Brown University; Jonathon Cohen, Emory University; Neil Palmisiano, Thomas Jefferson University; Elvira Umyarova, University of Vermont; Ryan A Wilcox, University of Michigan; Farrukh T Awan, Univ Texas Southwestern Med Ctr Dallas; Juan Pablo Alderuccio, University of Miami; Stefan K Barta, University of Pennsylvania; Natalie S Grover, University of North Carolina; Nilanjan Ghosh, Atrium Health; Nancy L Bartlett, Washington University; Alex F Herrera, Washington University; Geoffrey Shouse, City of Hope, Duarte
• Language: English
• Date: 2023-01-10
• Publisher: ELSEVIER
• Publication Version: Final Published Version
• Copyright Statement: © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1182/bloodadvances.2022008634
• Title of Journal or Parent Work: BLOOD ADVANCES
• Volume: 7
• Issue: 1
• Start Page: 88
• End Page: 91
• Keywords: Science & Technology; IBRUTINIB; LENALIDOMIDE; RITUXIMAB; Hematology; Life Sciences & Biomedicine

Abstract

Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin lymphoma that comprises 7% of all non-Hodgkin lymphomas.1, 2, 3 The optimal frontline management of MZL is not well defined, and the current treatment recommendations are adapted mainly from follicular lymphoma. With the advent of novel agents, the outcomes of MZL have improved significantly in the past decade.4 Ibrutinib, the first-in-class covalent Bruton tyrosine kinase inhibitor was approved for patients with relapsed/refractory (R/R) MZL based on the results of a phase 2 clinical trial wherein the overall response rate (ORR) was 48%.5 In the recently updated long-term follow-up of this study, the ORR was 58% with a median duration of response of 27.6 months.6 However, the outcomes of patients who progress on ibrutinib are largely unknown. Hence, we sought to evaluate the outcomes of patients with R/R MZL who experienced progression on ibrutinib therapy.